Phio.jpg
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)
16 avr. 2024 07h30 HE | Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is...
Global Antisense and RNAi Therapeutics Market
Global Antisense and RNAi Therapeutics Report 2024: A USD 34.7 Billion Predicted Market by 2034, with CAGR of 18% During 2024-2034
16 avr. 2024 07h26 HE | Research and Markets
Dublin, April 16, 2024 (GLOBE NEWSWIRE) -- The "Global Antisense and RNAi Therapeutics Market" report has been added to ResearchAndMarkets.com's offering.The global antisense and RNAi therapeutics...
Phio.jpg
Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)
11 avr. 2024 07h30 HE | Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is...
Phio.jpg
National Spotlight Features Phio’s Innovative RNAi Technology Platform
03 avr. 2024 07h30 HE | Phio Pharmaceuticals Corp.
—Program will be airing on PBS with Dennis Quaid in April —It will also be seen on Fox Business Network MARLBOROUGH, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp....
ADARx Pharmaceuticals Appoints Dr. Chris Storgard as Chief Medical Officer
02 avr. 2024 09h05 HE | ADARx Pharmaceuticals
ADARx Pharmaceuticals, next-generation RNA therapeutics developer, appoints Dr. Chris Storgard as Chief Medical Officer
Phio.jpg
Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update
02 avr. 2024 07h30 HE | Phio Pharmaceuticals Corp.
– Four sites across the country participating in clinical trial for lead product candidate PH-762 – Two patients have already completed treatment – New patent granted for skin related treatments,...
Phio.jpg
Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
21 mars 2024 07h30 HE | Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is...
Phio.jpg
Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research
13 mars 2024 14h00 HE | Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is...
Phio.jpg
Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders
06 mars 2024 10h30 HE | Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is...
22157.jpg
Global RNAi Technology Market Projected to Reach $1.9 Billion by 2028: Precision Medicine Integration Accelerating Personalized Treatments
12 févr. 2024 04h24 HE | Research and Markets
Dublin, Feb. 12, 2024 (GLOBE NEWSWIRE) -- The "RNAi Technology Market - Global Industry Size, Share, Trends Opportunity, and Forecast, 2028F" report has been added to ResearchAndMarkets.com's...